Boston Scientific announces recall of Lotus Valve devices

Boston Scientific Corporation ($BSX) announced that it plans to recall its Lotus Valve devices due to reports of a premature release of a pin connecting the valve to the delivery system. The problem is most likely caused by excess tension in the pin mechanism introduced during the manufacturing process. The [...]

By |February 24th, 2017|Opinions|0 Comments

HealthSouth announces strong quarterly results, provides guidance

HealthSouth Corp ($HLS) recently reported its quarterly numbers. Its earnings for the quarter stood at $0.72 per share, beating consensus estimates of $0.63 per share in earnings. The company’s revenue for the quarter stood at $949.9 million, lagging behind estimates of $955.6 million. The company also provided results for its [...]

By |February 23rd, 2017|Opinions|0 Comments

Lantheus reports Q4 results, new deal with GE

Lantheus Holdings Inc. (NASDAQ:LNTH) reported its financial results for the fourth quarter and full year 2016. It also provided guidance for the current year. The company’s revenue during the fourth quarter stood at 74.4 million, compared to $71.2 million for the fourth quarter of 2015. For the full year 2016, [...]

By |February 22nd, 2017|Opinions|0 Comments

Cellect Biotechnology reports positive results for ApoGraft trial

Cellect Biotechnology ($APOP) shot up 14 percent in the current trading session as the company announced positive results from its clinical trial of ApoGraft™ in healthy donors. The primary objective for the study was to validate the Company's propriety method of stem cell selection by going through the process of [...]

By |February 21st, 2017|Opinions|0 Comments

Gilead Sciences receives Canadian approval for HIV drug

Gilead Sciences Inc. ($GILD) announced that it has received approval in Canada for its ODEFSEY for treating HIV-1 infection. ODEFSEY is indicated in Canada as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) [...]

By |February 20th, 2017|Opinions|0 Comments

AstraZeneca reports positive Phase 2 results for cancer drug

AstraZeneca ($AZN) achieved an important milestone as the company announced that its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations met its [...]

By |February 17th, 2017|Opinions|0 Comments

Cryolife Inc. announces strong Q4 and financial year results

Cryolife Inc. ($CRY) stock jumped over 4 percent in its post-trading session as the company announced its fourth quarter and full year results for 2016. The company reported 13 percent Year over Year increase in its revenue to $45 million for the fourth quarter. The increase was mainly due to [...]

By |February 16th, 2017|Opinions|0 Comments

CIGNA terminates deal with Anthem, to sue for damages

CIGNA Corporation ($CI) announced that it has terminated its merger agreement with Anthem. The health insurer had $48 billion acquisition offer from Anthem. On February 8th, the U.S. District Court for the District of Columbia granted the U.S. Department of Justice’s request to block Anthem’s acquisition of Cigna. The Anthem [...]

By |February 15th, 2017|Opinions|0 Comments

Inovio Inks new deal with ApolloBio Corporation

Inovio Pharmaceuticals Inc. ($INO) announced its new collaboration with ApolloBio Corporation. The new pact deals with providing ApolloBio with the exclusive right to develop and commercialize VGX-3100, which is Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV). ApolloBio will have commercializing rights within Greater China [...]

By |February 14th, 2017|Opinions|0 Comments

Sage Therapeutics reports positive results from a Phase 2 trial

Sage Therapeutics ($SAGE) announced top line data from its Phase 2 clinical trial of orally-administered SAGE-217 for the treatment of major depressive disorder. The primary endpoint of the 13 patient Part A open-label trial was to evaluate safety and tolerability. SAGE-217 was found to be generally well-tolerated with no serious [...]

By |February 13th, 2017|Opinions|0 Comments

Sanofi Reports fourth quarter and full year results

Sanofi ($SNY) announced its fourth quarter net income at $852.2 million. Its net income, adjusted for non-recurring costs, stood at $0.67 per share. The drugmaker posted revenue of $9.56 billion for the same period. For the full financial year, the company’s reported profit stood at $5.21 billion, or $2.03 per [...]

By |February 10th, 2017|Opinions|0 Comments

Acorda Therapeutics ($ACOR) reports positive CVT-301 Results

Acorda Therapeutics ($ACOR) announced the results from a late-stage clinical trial of the drug candidate, CVT-301. The result showed that the inhaled formulation of levodopa improved the motor function of Parkinson's disease patients during so-called "off" periods when their symptoms re-emerge. Acorda is seeking approval for CVT-301 as a treatment [...]

By |February 9th, 2017|Opinions|0 Comments

Humana Reports Fourth Quarter Results

Humana Inc. (NYSE:HUM) reported better than expected results for the fourth quarter. The company announced its fourth quarter net loss at $401 million or $2.68 per share. Humana had reported the net income of $101 million, or $0.67 per share, a year earlier. The loss mainly arose due to a [...]

By |February 8th, 2017|Opinions|0 Comments

Benitec Biopharma ($BNTC) Pursues Oncology and Ocular Trials

Benitec Biopharma ($BNTC) announced that it has significant milestone with regard to its ddRNAi technology to treat ocular diseases, particularly with identifying novel viral vectors. The new development will enable the delivery of the gene therapy to the retina via intravitreal injection. Current ocular gene therapy requires a complex surgical [...]

By |February 7th, 2017|Opinions|0 Comments

MediWound ($MDWD) receives permission to expand study population scope

MediWound ($MDWD) announced that it has been granted that it has received endorsement from The European Medicines Agency for expanding the patient population in Phase 3 Children Innovative Debridement Study (CIDS) to include burn patients at least one year old instead of four years old. The recommendation was made by [...]

By |February 6th, 2017|Opinions|0 Comments

Palatin Technologies ($PTN) closes deal with Amagen

Palatin Technologies Inc. ($PTN) recently announced the closing of its licensing agreement with Amagen Pharmaceuticals, Inc. ($AMAG) for exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide). The drug is an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women. The licensing agreement [...]

By |February 3rd, 2017|Opinions|0 Comments

Mylan NV ($MYL) reports antitrust investigation

Mylan NV ($MYL) announced that it is being investigating by the US antitrust authorities for its EpiPen emergency allergy treatment. The company was earlier asked for information by the Federal Trade Commission as part of a preliminary investigation. The company had been severely criticized for raising the price of a [...]

By |February 2nd, 2017|Opinions|0 Comments

Ophthotech Corp ($OPHT) appoints new CFO and COO

Ophthotech Corp ($OPHT) reported it is looking at strategic alternatives for maximizing returns to its shareholders. The main focus of the plan will be on obtaining rights to additional products, product candidates and technologies to treat ophthalmic diseases, particularly those of the back of the eye. As part of the [...]

By |February 1st, 2017|Opinions|0 Comments

Sanofi ($SNY) gets sued for insulin price increase

Drug companies have come under fire for exorbitant increase in their drug prices. A lawsuit, filed on Monday in a federal court in Massachusetts, has named Sanofi SA ($SNY), Novo Nordisk ($NVO) and Eli Lilly and Co ($LLY). The case pertains to price fixing as it claimed that the companies [...]

By |January 31st, 2017|Opinions|0 Comments

Emergent BioSolutions ($EBS) get approval for new construction site in Germany

Emergent BioSolutions ($EBS) announced receiving approval from German Federal Ministry of Health for the construction of Building 55. The building will be used for manufacturing BioThrax. The approval will also allow the company to market the drug in Germany. Currently, BioThrax is the only anthrax vaccine licensed by the Paul-Ehrlich-Institut [...]

By |January 30th, 2017|Opinions|0 Comments
s2Member®